SMTL ID : 9nfb.1

Structure of the cross-HLA supertype antibody R302 bound to a class I MHC presenting a divarasib-modified KRAS-G12C peptide on HLA-A*02

Coordinates

PDB Format Compare

Method

ELECTRON MICROSCOPY

Oligo State

hetero-1-1-1-1-1-mer

Ligands

1 x 01: 1-{(3S)-4-[(7M)-7-[6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl]-6-chloro-8-fluoro-2-{[(2S)-1-methylpyrrolidin-2-yl]methoxy}quinazolin-4-yl]-3-methylpiperazin-1-yl}propan-1-one

01.1: 14 residues within 4Å: Chain A: R.66, T.74 Chain C: V.4, C.8 Chain D: D.1, S.92, A.95 Chain E: H.35, V.50, S.52, N.57, Y.59, Y.60, D.62 10 PLIP interactions: 3 interactions with chain D, 1 interactions with chain C, 5 interactions with chain E, 1 interactions with chain A Hydrogen bonds: D:A.95, D:A.95, A:T.74 Salt bridges: D:D.1, E:D.62 Hydrophobic interactions: C:V.4, E:V.50 pi-Stacking: E:Y.59, E:Y.59 Halogen bonds: E:N.57

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Maso, L. et al., Engineered antibodies that stabilize drug-modified KRASG12C neoantigens enable selective and potent cross-HLA immunotherapy. To Be Published

Release Date

2025-10-08

Peptides

MHC class I antigen: A
Beta-2-microglobulin: B
GTPase KRas: C
R302 Fab light chain: D
R302 Fab heavy chain: E

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

B
B

C
C

D
D

E
E

MHC class I antigen

Beta-2-microglobulin

GTPase KRas

R302 Fab light chain

R302 Fab heavy chain

Related Entries With Identical Sequence